Summary & Overview
HCPCS J3303: Triamcinolone Hexacetonide Injection, per 5 mg
HCPCS Level II code J3303 denotes the administration of triamcinolone hexacetonide in 5 mg units, a long-acting corticosteroid commonly used for intra-articular and soft-tissue injections to manage inflammatory musculoskeletal conditions. Nationally, this code matters because it captures use of a specific depot steroid formulation with implications for procedure documentation, drug utilization monitoring, and payer coverage policies.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the medication, typical sites of service where the injection is performed, and common billing considerations tied to the code. The publication outlines benchmarks and coverage patterns where available, summarizes relevant policy updates affecting HCPCS Level II drug billing, and highlights operational details that affect claims submission and coding accuracy.
This summary is intended to orient clinicians, billing professionals, and policy analysts to the core purpose and billing environment of J3303, and to indicate what further details—such as payer-specific reimbursement benchmarks, modifier usage, and related billing codes—are addressed in the full publication.
Billing Code Overview
HCPCS Level II code J3303 represents an injection of triamcinolone hexacetonide, per 5 mg. This medication is a long-acting corticosteroid formulation used for intra-articular or soft-tissue injections to reduce inflammation in musculoskeletal and rheumatologic conditions.
-
Service type: Therapeutic corticosteroid injection
-
Typical site of service: Outpatient clinic, physician office, ambulatory surgical center, or other outpatient procedural setting
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with a localized inflammatory joint or periarticular condition (for example, juvenile idiopathic arthritis, rheumatoid arthritis, or a steroid-responsive bursitis/tenosynovitis) presenting for image-guided or clinician-guided intra-articular or periarticular steroid injection. The clinician (rheumatologist, orthopedic surgeon, physiatrist, pediatric rheumatologist, or interventional radiologist) documents the indication, informed consent, allergies, and prior steroid response. The workflow includes pre-procedure assessment (vital signs, medication review including anticoagulants), site preparation, sterile technique, aspiration if effusion present, and injection of J3303 dosed in 5 mg increments depending on joint size and indication. Post-procedure observation for immediate adverse effects and written aftercare instructions are provided. The typical site of service is an ambulatory clinic procedure room, hospital outpatient department, or ambulatory surgery center when image guidance is required. Common scenarios include single-joint flare management, diagnostic therapeutic injection, or chronic disease control when systemic therapy is insufficient or contraindicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work or complexity substantially exceeds typical injection complexity (document justification). |